Cargando…

Acute Inflammatory Demyelinating Polyneuroradiculopathy with Ipilimumab in Metastatic Melanoma: A Case Report and Review of Literature

Ipilimumab (Bristol-Myers Squibb Co., New York, NY) is a novel anticancer medication used for the treatment of metastatic melanoma. The exact mechanism of its action remains unclear; however, data from previous clinical trials postulates the immunomodulatory activity of ipilimumab to enhance therape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rupareliya, Chintan, Naqvi, Syeda, Jani, Vishal B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498115/ https://www.ncbi.nlm.nih.gov/pubmed/28690944 http://dx.doi.org/10.7759/cureus.1310

Ejemplares similares

Alexia Without Agraphia: A Rare Entity
por: Rupareliya, Chintan, et al.
Publicado: (2017)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature
por: Braden, Jorja, et al.
Publicado: (2021)

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
por: Mullinax, John E., et al.
Publicado: (2018)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
por: Vázquez-Montero, Lucía, et al.
Publicado: (2023)

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
por: Reiter, Selina, et al.
Publicado: (2023)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
por: Khimani, Karima, et al.
Publicado: (2022)

Pineal Gland Tumor but not Pinealoma: A Case Report
por: Naqvi, Syeda, et al.
Publicado: (2017)

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
por: Cafuir, Lorraine, et al.
Publicado: (2018)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab
por: Burgos, Remberto, et al.
Publicado: (2022)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review
por: Barnabei, Agnese, et al.
Publicado: (2020)

Metastatic Melanoma to the Bladder: Case Report and Review of the Literature
por: Patil, Rohit V., et al.
Publicado: (2017)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
por: McDonald, Marin A., et al.
Publicado: (2018)

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
por: Wolfe, Zachary, et al.
Publicado: (2022)

Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases
por: Nguyen, Steven M, et al.
Publicado: (2017)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

Bleeding Diathesis or Fabrication: Munchausen Syndrome
por: Naqvi, Syeda, et al.
Publicado: (2017)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2020)

Burden of Arrhythmias in Epilepsy Patients: A Nationwide Inpatient Analysis of 1.4 Million Hospitalizations in the United States
por: Desai, Rupak, et al.
Publicado: (2017)

Wernicke’s Encephalopathy as a Rare Complication of Hyperemesis Gravidarum: A Case Report and Review of Literature
por: Nagarajan, Elanagan, et al.
Publicado: (2018)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
por: Montes, Vera, et al.
Publicado: (2018)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
por: Chu, Michael P., et al.
Publicado: (2020)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels
por: Leung, Anna M., et al.
Publicado: (2014)

Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma
por: Schmidt, Teresa, et al.
Publicado: (2021)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
por: Nakamura, Yoshiyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dc5ddofn7sfhvst6duq9tanuf8